Evidence map›Paper›PMID 37160500›Full record

ReviewJournal of patient-reported outcomes2023

Development and validation of fear of hypoglycemia screener: results from the T1D exchange registry.

Jingwen Liu, Jiat-Ling Poon, Jeoffrey Bispham, Magaly Perez-Nieves, Allyson Hughes, Katherine Chapman, Beth Mitchell, Korey Hood, Frank Snoek, Lawrence Fisher

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of patient-reported outcomes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Jingwen Liu *T1D Exchange, Boston, MA, USA.
Jiat-Ling PoonEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
Jeoffrey Bispham *T1D Exchange, Boston, MA, USA.
Magaly Perez-NievesEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
Allyson Hughes *T1D Exchange, Boston, MA, USA.
Katherine ChapmanT1D Exchange, Boston, MA, USA.
Beth MitchellEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. mitchell_beth_d@lilly.com.
Korey HoodStanford University School of Medicine, Stanford, CA, USA.
Frank SnoekDepartment of Medical Psychology Amsterdam University Medical Centres, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Lawrence FisherDepartment of Family and Community Medicine, University of California San Francisco, San Francisco, CA, USA.
T1D Exchange · USEli Lilly (United States) · USAmsterdam University Medical Centers · NLStanford University · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFear of Hypoglycemia (FoH) in people with diabetes has a significant impact on their quality of life, psychological well-being, and self-management of disease. There are a few questionnaires assessing FoH in people living with diabetes, but they are more often used in research than clinical practice. This study aimed to develop and validate a short and actionable FoH screener for adults living with type 1 diabetes (T1D) for use in routine clinical practice.

methodsWe developed an initial screener based on literature review and, interviews with healthcare providers (HCPs) and people with T1D. We developed a cross-sectional web-based survey, which was then conducted to examine the reliability and validity of the screener. Adults (aged ≥ 18 years) with diagnosis of T1D for ≥ 1 year were recruited from the T1D Exchange Registry (August-September 2020). The validation analyses were conducted using exploratory factor analyses, correlation, and multivariable regression models for predicting cut-off scores for the final screener.

resultsThe final FoH screener comprised nine items assessing two domains, "worry" (6-items) and "avoidance behavior" (three items), in 592 participants. The FoH screener showed good internal consistency (Cronbach's α = 0.88). The screener also demonstrated high correlations (r = 0.71-0.75) with the Hypoglycemia Fear Survey and moderate correlations with depression, anxiety, and diabetes distress scales (r = 0.44-0.66). Multivariable regression analysis showed that higher FoH screener scores were significantly associated with higher glycated hemoglobin (HbA1c) (b = 0.04) and number of comorbidities (b = 0.03).

conclusionsThis short FoH screener demonstrated good reliability and validity. Further research is planned to assess clinical usability to identify patients with FoH and assist effective HCP-patient conversations.

Indexed as

Diabetes Mellitus, Type 1HypoglycemiaAdultCross-Sectional StudiesFearHumansQuality of LifeReproducibility of ResultsBehavior scaleFear of hypoglycemiaT1DWorry scale

Identifiers

PMID37160500
PMCPMC10169988
OpenAlexW4376132857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.